Arcturus Therapeutics Holdings Inc., a San Diego-based biotechnology firm, operates at the cutting edge of genetic instruction, essentially designing the cellular equivalent of software updates for the human body. Their core mission involves developing messenger RNA (mRNA) medicines and vaccines, acting as tiny couriers delivering precise molecular blueprints to cells. This intricate process aims to reprogram the body's own machinery to produce therapeutic proteins or mount immune responses, a high-stakes endeavor where the biological operating system often proves stubbornly uncooperative.

The company’s arsenal includes two proprietary platforms: the LUNAR® lipid-mediated delivery system, which encapsulates and transports these delicate mRNA payloads, and the STARR™ self-amplifying mRNA technology, designed to generate more protein from smaller doses, theoretically offering a more efficient, albeit complex, biological whisper campaign. Their pipeline targets a diverse range of ailments, from rare liver and respiratory diseases like cystic fibrosis (ARCT-032) and ornithine transcarbamylase (OTC) deficiency (ARCT-810), both in Phase 2 clinical trials, to infectious disease vaccines, including the recently re-acquired global rights to KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine already approved in Japan and the EU.

Arcturus operates with a hybrid business model, generating revenue primarily through collaborations, milestones, and licensing agreements rather than a broad catalog of commercial products. While headquartered in California, its reach is decidedly global, extending through clinical trials, regulatory bodies, and partnerships across Asia-Pacific and Europe. Their competitive edge lies in their extensive patent portfolio, boasting over 500 patents and applications protecting their innovative mRNA and delivery technologies. However, the path of molecular enlightenment is fraught with peril; the company recently faced investor scrutiny and class-action lawsuits following disappointing Phase 2 results for its cystic fibrosis candidate, ARCT-032, which failed to show meaningful lung function improvement, causing a significant stock plunge in October 2025. This setback, alongside ongoing litigation alleging trade secret misappropriation against AbbVie and Capstan Therapeutics, and historic legal battles with a former CEO, highlights the volatile, high-stakes nature of pioneering genetic medicine.